Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

GKL-006Allo Injection in Patients With Advanced Solid Tumors

14 de julio de 2026 actualizado por: Beijing Gene Key Life Technology Co., Ltd

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006Allo Injection in Patients With Solid Tumors

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.

Descripción general del estudio

Estado

Aún no reclutando

Intervención / Tratamiento

Descripción detallada

This Phase 1 study will evaluate GKL-006Allo Injection in participants with advanced or metastatic solid tumors who have failed or are intolerant to standard therapy.

The study includes single-dose and multiple-dose treatment, with a potential dose-expansion stage to further evaluate selected dose level according to protocol-specified criteria. The single-dose and multiple-dose stages are designed to characterize safety, tolerability, and biological activity across protocol-specified dose levels.

Participants will receive GKL-006Allo Injection according to the study protocol and will undergo scheduled safety monitoring, tumor assessments, pharmacokinetic and pharmacodynamic sampling, and immunogenicity testing during treatment and follow-up.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

27

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Cancer Hospital Chinese Academy of Medical Sciences
  • Número de teléfono: +86-316-5916013
  • Correo electrónico: lining@cisams.ac.cn

Ubicaciones de estudio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Able to understand and voluntarily sign the informed consent form.
  • Aged 18 to 75 years.
  • Histologically, cytologically or clinical confirmed unresectable locally advanced or metastatic solid tumor that has failed standard therapy.
  • At least one measurable tumor lesion during screening according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and life expectancy of at least 3 months.
  • Adequate hematologic and organ function.
  • Participants of childbearing potential must agree to use at least one medically accepted contraceptive method during study treatment and for 6 months after the end of study treatment.
  • Able to communicate with the investigator, comply with study visits, and understand and follow study requirements.

Exclusion Criteria:

  • Recently received radical radiotherapy or other anti-tumor therapy.
  • Known hypersensitivity to any component of the study treatment.
  • Prior history or concurrent malignancy that has not been cured.
  • Active infection, known or suspected autoimmune disease.
  • Last anti-tumor treatment toxicity not yet recovered to suitable status.
  • Other organ dysfunction or situations deemed inappropriate by the investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: GKL-006Allo Injection
Natural killer T cells (NKT) are a type of special lymphocyte discovered in recent years that mediate both innate and adaptive immunity, and are considered the fourth type of lymphocyte. GKL-006Allo is an allogeneic iNKT cell.
GKL-006Allo Injection is an allogeneic invariant natural killer T (iNKT) cell therapy. It will be administered according to the dose level, dosing schedule, and treatment stage specified in the protocol.
Otros nombres:
  • Allogeneic iNKT Cell Therapy
  • Allogeneic invariant natural killer T cell therapy

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants With Dose-Limiting Toxicities (DLTs)
Periodo de tiempo: From the first dose through the end of the DLT observation period, assessed up to 28 days.
Dose-limiting toxicities will be assessed according to protocol-defined DLT criteria.
From the first dose through the end of the DLT observation period, assessed up to 28 days.
Incidence and Severity of Adverse Events
Periodo de tiempo: From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.
Safety will be assessed by the incidence and severity of adverse events, serious adverse events, laboratory abnormalities, electrocardiogram abnormalities, physical examination findings, and vital sign abnormalities.
From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-Free Survival (PFS)
Periodo de tiempo: From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
Progression-free survival is defined as the time from the first dose of study treatment to the first documented disease progression or death from any cause, whichever occurs first, according to RECIST v1.1.
From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
Overall Survival (OS)
Periodo de tiempo: From the first dose of study treatment until death from any cause, assessed up to 18 months.
Overall survival is defined as the time from the first dose of study treatment to death from any cause.
From the first dose of study treatment until death from any cause, assessed up to 18 months.
Change From Baseline in EORTC QLQ-C30 Scale Scores
Periodo de tiempo: Baseline and scheduled post-baseline assessments, up to 18 months.
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores for each scale range from 0 to 100. Higher scores on the functional scales and global health status/quality-of-life scale indicate better functioning or quality of life.
Baseline and scheduled post-baseline assessments, up to 18 months.
Immunogenicity
Periodo de tiempo: From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
GKL-006 Alloantibodies (ADA) and their titers, anti-GKL-006 Allo neutralizing antibodies (Nab) and their titers, anti-HLA antibodies, etc. will be tested.
From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
Disease Control Rate (DCR)
Periodo de tiempo: From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Disease control rate is defined as the proportion of participants with a best overall response of complete response, partial response, or stable disease according to RECIST v1.1.
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Objective Response Rate (ORR)
Periodo de tiempo: From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Objective response rate is defined as the proportion of participants with a best overall response of complete response or partial response according to RECIST v1.1.
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Pharmacokinetic characterization of maximum observed plasma concentration (Cmax)
Periodo de tiempo: From 60 minutes before the first dose through 150 days.
Maximum observed plasma concentration of GKL-006 following intravenous administration according to protocol.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of time to maximum observed plasma concentration (Tmax)
Periodo de tiempo: From 60 minutes before the first dose through 150 days.
Time to reach the maximum observed plasma concentration of GKL-006 following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of area under the plasma concentration-time curve (AUC)
Periodo de tiempo: From 60 minutes before the first dose through 150 days.
Area under the plasma concentration-time curve of GKL-006 following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of terminal elimination half-life (t½)
Periodo de tiempo: From 60 minutes before the first dose through 150 days.
Terminal elimination half-life of GKL-006 calculated from plasma concentration-time data following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of NK cells
Periodo de tiempo: From 60 minutes before the first dose through 150 days.
Immune cell subsets
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of Peripheral blood TNF-α
Periodo de tiempo: From 60 minutes before the first dose through 150 days.
Immune-related cytokines
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of Peripheral blood IFN-γ
Periodo de tiempo: From 60 minutes before the first dose through 150 days.
Immune-related cytokines
From 60 minutes before the first dose through 150 days.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Ning Li, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

30 de agosto de 2026

Finalización primaria (Estimado)

30 de septiembre de 2028

Finalización del estudio (Estimado)

31 de enero de 2029

Fechas de registro del estudio

Enviado por primera vez

9 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de julio de 2026

Publicado por primera vez (Actual)

15 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

15 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de julio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • GKL006ALLOST01

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir